Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-β receptor inhibitor on extravasation of nanoparticles from neovasculature

Cancer Science

Volumn 100, Issue 1, 2009, Pages 173-180

  Kano, Mitsunobu R ^a,b,c   Komuta, Yukari ^a,d   Iwata, Caname ^a   Oka, Masako ^a   Shirai, Yo Taro ^a   Morishita, Yasuyuki ^a   Ouchi, Yasuyoshi ^a   Kataoka, Kazunori ^b   Miyazono, Kohei ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Japan Association for the Advancement of Medical Equipment   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; DEXTRAN; IMATINIB; LY 364947; NANOPARTICLE; PROTEIN KINASE INHIBITOR; SMOOTH MUSCLE ACTIN; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EXTRAVASATION; DRUG POTENCY; MOUSE; NONHUMAN; PANCREAS CANCER; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; BENZENESULFONATES; CELL LINE, TUMOR; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HUMANS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; PYRROLES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58149284060     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01003.x     Document Type: Article

References (25)

1. Giroux V, Malicet C, Barthet M et al. p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res 2006; 12: 235-41.
2. Merriman RL, Hertel LW, Schultz RM et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 1996; 14: 243-7.
3. Rothenberg ML, Moore MJ, Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-53.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
5. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50: 814S-19S.
6. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006; 98: 335-44.
7. Kano MR, Bae Y, Iwata C et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci USA 2007; 104: 3460-5.
8. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
9. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44.
10. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 2005; 7: 452-64.
11. von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell Res 2006; 312: 623-9.
12. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003; 112: 1142-51.
13. Lindblom P, Gerhardt H, Liebner S et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003; 17: 1835-40.
14. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-4.
15. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-95.
16. Kano MR, Morishita Y, Iwata C et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRβ signaling. J Cell Sci 2005; 118: 3759-68.
17. Vlahovic G, Rabbani ZN, Herndon JE, Dewhirst MW, Vujaskovic Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 2006; 95: 1013-19.
18. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-21.
19. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
20. Hirschi KK, Rohovsky SA, D'Amore PA. PDGF, TGF-β, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 1998; 141: 805-14.
21. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008; 5: E19.
22. Micke P, Ostman A. Tumour-stroma interaction: Cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004; 45: S163-75.
23. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005; 15: 97-101.
24. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-12.
25. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005; 97: 512-23.